HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Clinical analysis of 81 cases of malignant lymphoma treated with autologous hematopoietic stem cell transplantation].

AbstractOBJECTIVE:
To investigated the curative effect of autologous hematopoietic stem cell transplantation (ASCT) for malignant lymphoma.
METHODS:
The clinical data of 81 patients with malignant lymphoma received ASCT from April 1999 to October 2013 were retrospectively analyzed. Of 81 patients, 70 were non-Hodgkin's lymphoma (NHL) and 11 Hodgkin's lymphoma (HL). High dose of etoposide combined with G-CSF was used to mobilize peripheral hematopoietic stem cell. Preconditioning regimen was BEAM (carmustine + cytarabine + etoposide + melphalan).
RESULTS:
Enough peripheral blood stem cells were collected from all patients. All of the patients after transplantation achieved hematopoietic reconstitution, the median time of the absolute neutrophil count (ANC) recovery to >0.5×10⁹/L time was 10(7-16) d, and the median time of platelet count recovery to >20×10⁹/L was 10(6-17) d. With the follow-up of 23(2-139) months, progression free survival (PFS) was 72.7%, and overall survival (OS) was 88.6%. The median PFS and OS were not reached. Complete remission (CR) before ASCT was an independent prognostic factor of PFS. No transplant related death happened.
CONCLUSION:
ASCT was a safe and effective method for treatment of malignant lymphoma.
AuthorsLi Wang, Lei Fan, Kourong Miao, Ji Xu, Run Zhang, Ming Hong, Huayuan Zhu, Wenyi Shen, Xiaoyan Zhang, Lijuan Chen, Hongxia Qiu, Hua Lu, Peng Liu, Hanxin Wu, Wei Xu, Jianyong Li
JournalZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi (Zhonghua Xue Ye Xue Za Zhi) Vol. 35 Issue 4 Pg. 328-31 (Apr 2014) ISSN: 0253-2727 [Print] China
PMID24759022 (Publication Type: English Abstract, Journal Article)
Topics
  • Adolescent
  • Adult
  • Aged
  • Female
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Lymphoma (therapy)
  • Male
  • Middle Aged
  • Retrospective Studies
  • Transplantation, Autologous

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: